UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000001891
Receipt number R000002278
Scientific Title Comparative Efficacy of Pioglitazone and Metformin in Glucose Variability in Type 2 Diabetes
Date of disclosure of the study information 2009/04/15
Last modified on 2012/04/17 14:33:55

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Comparative Efficacy of Pioglitazone and Metformin in Glucose Variability in Type 2 Diabetes

Acronym

Comparative Efficacy of Pioglitazone and Metformin in Glucose Variability in Type 2 Diabetes

Scientific Title

Comparative Efficacy of Pioglitazone and Metformin in Glucose Variability in Type 2 Diabetes

Scientific Title:Acronym

Comparative Efficacy of Pioglitazone and Metformin in Glucose Variability in Type 2 Diabetes

Region

Japan


Condition

Condition

type 2 diabetes

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To compare glucose variability in patients given pioglitazone or metformin by using continuous glucose monitoring (CGM).

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Glucose variability in CGM (area under the glucose curve from pre-meal baseline to baseline, pattern of glucose curve, magnitude of increase in glucose levels and the time to peak glucose levels from baseline after each meal)

Key secondary outcomes

Pre-meal plasma glucose, 2 hour post prandial glucose, side effect, body weight change


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

pioglitazone

Interventions/Control_2

metformin

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

Type 2 diabetic patients on no other antidiabetic medications (6.0=<HbA1c<10.0%, BMI>=25kg/m2)

Key exclusion criteria

Patients with type 1 diabetes, patients with severe liver disease, patients with severe renal disease, patients with severe heart disease, patients with history of myocardial infarction within 6 months, patients with severe pancreatic disease, cancer patients, patients with severe diabetic neuropathy, patients with severe diabetic retinopathy, patients with history of lactic acidosis, heavy drinkers, pregnant patients

Target sample size

20


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Aya Morimoto

Organization

Jikei University School of Medicine

Division name

Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine

Zip code


Address

3-25-8, Nishishinbashi, Minato-ku, Tokyo, Japan

TEL

03-3433-1111

Email



Public contact

Name of contact person

1st name
Middle name
Last name Aya Morimoto

Organization

Jikei University School of Medicine

Division name

Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine

Zip code


Address

3-19-18, Nishisinbashi, Minato-ku, Tokyo

TEL

03-3433-1111

Homepage URL


Email



Sponsor or person

Institute

Jikei University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2009 Year 04 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2009 Year 02 Month 01 Day

Date of IRB


Anticipated trial start date

2009 Year 02 Month 01 Day

Last follow-up date

2011 Year 01 Month 01 Day

Date of closure to data entry

2011 Year 01 Month 01 Day

Date trial data considered complete

2011 Year 01 Month 01 Day

Date analysis concluded

2011 Year 02 Month 01 Day


Other

Other related information



Management information

Registered date

2009 Year 04 Month 15 Day

Last modified on

2012 Year 04 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002278


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name